All In Biotech

NDA 214985 · Idorsia

Quviviq

Daridorexant Hydrochloride · Oral · Orexin Receptor Antagonist

Novel

CDER novel approval, Jan 7, 2022: To treat insomnia

Last checked: Nov 19, 2026Latest source record: Sep 30, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Jan 7, 2022

Approved uses

3

Original approval plus efficacy supplements

Registered trials

49

6 Phase 3, 7 recruiting

FAERS reports

2,777

996 serious, 78 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 26, 2026.

QUVIVIQ is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance [see Clinical Studies (14.1) ] . QUVIVIQ is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. ( 1 )

Mechanism: The mechanism of action of daridorexant in the treatment of insomnia is presumed to be through antagonism of orexin receptors. The orexin neuropeptide signaling system plays a role in wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive.

Therapeutic areas: Psychiatry

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • QUVIVIQ · DARIDOREXANT HYDROCHLORIDE EQ 50MG BASE · TABLET, ORAL · Prescription
  • QUVIVIQ · DARIDOREXANT HYDROCHLORIDE EQ 25MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Daridorexant" as an intervention, any sponsor and status, largest first.

All 49 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective482
  • insomnia327
  • nightmare281
  • somnolence183
  • fatigue171
  • headache168
  • product availability issue148
  • abnormal dreams137
  • feeling abnormal124
  • inappropriate schedule of product administration122
  • suicidal ideation100
  • dizziness98

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20201
20211
2022505
20231,154
2024217
2025402
2026497

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Quviviq (Daridorexant HCl)

2024 spending

$24.4M

Beneficiaries

12,891

46,269 claims

Per beneficiary

$1,891

$16.30 per unit

View as table
YearSpending
2020$0
2021$0
2022$2,396,493
2023$16,342,719
2024$24,381,569

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 57 on PubMed

Sponsor: Idorsia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.